Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant | Zendy

Shabir A. Madhi | Zendy; Vicky L. Baillie | Zendy; Clare Cutland | Zendy; Merryn Voysey | Zendy; Anthonet Koen | Zendy; Lee Fairlie | Zendy; Sherman D. Padayachee | Zendy; Keertan Dheda | Zendy; Shaun Barnabas | Zendy; Qasim Bhorat | Zendy; Carmen Briner | Zendy; Gaurav Kwatra | Zendy; Khatija Ahmed | Zendy; Parvinder K. Aley | Zendy; Sutika Bhikha | Zendy; Jinal N. Bhiman | Zendy; As’ad E. Bhorat | Zendy; Jeanine du Plessis | Zendy; Aliasgar Esmail | Zendy; Marisa Groenewald | Zendy; Elizea Horne | Zendy; Shi-Hsia Hwa | Zendy; Aylin Jose | Zendy; Teresa Lambe | Zendy; Matt Laubscher | Zendy; Mookho Malahleha | Zendy; Masebole Masenya | Zendy; Mduduzi Masilela | Zendy; Shakeel McKenzie | Zendy; Kgaogelo Molapo | Zendy; Andrew Moultrie | Zendy; Suzette Oelofse | Zendy; Faeezah Patel | Zendy; Sureshnee Pillay | Zendy; Sarah Rhead | Zendy; Hylton Rodel | Zendy; Lindie Rossouw | Zendy; Carol Taoushanis | Zendy; Houriiyah Tegally | Zendy; Asha Thombrayil | Zendy; Samuel van Eck | Zendy; Constantinos Kurt Wibmer | Zendy; Nicholas M. Durham | Zendy; Elizabeth J. Kelly | Zendy; Tonya Villafana | Zendy; Sarah C. Gilbert | Zendy; Andrew J. Pollard | Zendy; Túlio de Oliveira | Zendy; Penny L. Moore | Zendy; Alex Sigal | Zendy; Alane Izu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

Author(s) -

Shabir A. Madhi,

Vicky L. Baillie,

Clare Cutland,

Merryn Voysey,

Anthonet Koen,

Lee Fairlie,

Sherman D. Padayachee,

Keertan Dheda,

Shaun Barnabas,

Qasim Bhorat,

Carmen Briner,

Gaurav Kwatra,

Khatija Ahmed,

Parvinder K. Aley,

Sutika Bhikha,

Jinal N. Bhiman,

As’ad E. Bhorat,

Jeanine du Plessis,

Aliasgar Esmail,

Marisa Groenewald,

Elizea Horne,

Shi-Hsia Hwa,

Aylin Jose,

Teresa Lambe,

Matt Laubscher,

Mookho Malahleha,

Masebole Masenya,

Mduduzi Masilela,

Shakeel McKenzie,

Kgaogelo Molapo,

Andrew Moultrie,

Suzette Oelofse,

Faeezah Patel,

Sureshnee Pillay,

Sarah Rhead,

Hylton Rodel,

Lindie Rossouw,

Carol Taoushanis,

Houriiyah Tegally,

Asha Thombrayil,

Samuel van Eck,

Constantinos Kurt Wibmer,

Nicholas M. Durham,

Elizabeth J. Kelly,

Tonya Villafana,

Sarah C. Gilbert,

Andrew J. Pollard,

Túlio de Oliveira,

Penny L. Moore,

Alex Sigal,

Alane Izu

Publication year - 2021

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2102214

Subject(s) - placebo , medicine , virology , neutralization , clinical endpoint , virus , vaccine efficacy , randomized controlled trial , coronavirus , covid-19 , clinical trial , immunology , vaccination , disease , pathology , alternative medicine , infectious disease (medical specialty)

Assessment of the safety and efficacy of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is investigation of the efficacy of the vaccines against emerging SARS-CoV-2 variants of concern, including the B.1.351 (501Y.V2) variant first identified in South Africa.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research